Riskpilot← Back to searchSign inGet full accessNAPRAPATSENTERET AS
ASActiveOrg 918563466Torggata 10, 0181 OsloTraditional, complementary and alternative medicine activities · NACE 8696Est. 20171 employees
Revenue 2024
NOK 2,7M
+1% vs 2023
EBITDA margin
-4.6%
+37% vs 2023
Equity ratio
-73.8%
Financial strength
Net profit 2024
NOK -121K
+38% vs 2023
| Revenue | NOK 2,7M | +1% |
| EBITDA | NOK -124K | +37% |
| Net profit | NOK -121K | +38% |
| Total assets | NOK 628K | +12% |
| Equity | NOK -463K | -36% |
| Employees | 1 | — |
Legal name
NAPRAPATSENTERET AS
Org number
918563466
Legal form
Aksjeselskap
NACE code
8696 · Traditional, complementary and alternative medicine activities
Founded
23. februar 2017
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og nestleder hver for seg. Styrets leder alene.
Company purpose
Selskapets virksomhet er behandling av muskler og leddproblemer og andre produkter/tjenester som naturlig hører til dette, herunder å delta i andre selskap med lignende virksomhet, og kjøp og salg av aksjer eller på annen måte gjøre seg interessert i andre foretak.
Address
Torggata 10, 0181 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 988 | 2 849 | 2 639 | 2 648 | 2 687 |
| Staff expenses | −618 | −228 | −717 | −547 | −481 |
| EBITDA | −69 | 241 | −481 | −197 | −124 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −69 | 241 | −481 | −197 | −124 |
| Net financials | −0 | 1 | 0 | 1 | 2 |
| Profit before tax | −69 | 242 | −481 | −196 | −121 |
| Tax | −0 | 40 | −0 | −0 | −0 |
| Net profit | −69 | 202 | −481 | −196 | −121 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 710 | 910 | 505 | 560 | 628 |
| Equity | 133 | 335 | −146 | −342 | −463 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 577 | 575 | 651 | 902 | 1 091 |
| Total debt | 577 | 575 | 651 | 902 | 1 091 |
EBITDA margin
-4.6%
This company
15.8%
Market median
-129% vs market
20202024
Equity ratio
-73.8%
This company
38.2%
Market median
-293% vs market
20202024
Return on equity
-12144500.0%
This company
18.4%
Market median
-66002817% vs market
20202024
Net profit margin
-4.5%
This company
8.1%
Market median
-156% vs market
20202024
Asset turnover
4.28×
This company
1.12×
Market median
+282% vs market
20202024
Debt / equity
2.35×
This company
0.62×
Market median
-279% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GR Chief Executive Officer | Chief Executive Officer | 2017 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Anatomix Holding As
NAPRAPATSENTERET AS Board members of NAPRAPATSENTERET AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Guy Robert Giltun | Chief Executive Officer | 0 companies |